JP5373393B2 - ヒドロキシアミノ基またはアシルオキシアミノシクロアルキル基を含むプレウロムチリン誘導体 - Google Patents

ヒドロキシアミノ基またはアシルオキシアミノシクロアルキル基を含むプレウロムチリン誘導体 Download PDF

Info

Publication number
JP5373393B2
JP5373393B2 JP2008518554A JP2008518554A JP5373393B2 JP 5373393 B2 JP5373393 B2 JP 5373393B2 JP 2008518554 A JP2008518554 A JP 2008518554A JP 2008518554 A JP2008518554 A JP 2008518554A JP 5373393 B2 JP5373393 B2 JP 5373393B2
Authority
JP
Japan
Prior art keywords
mutilin
amino
acetyl
cycloalkyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008518554A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008546810A5 (cg-RX-API-DMAC7.html
JP2008546810A (ja
Inventor
マング,ローズマリー
アシャー,ゲルド
フェレンチック,マティアス
ハイルマイヤー,ヴェルナル
ノヴァック,ロドガー
Original Assignee
ナブリヴァ セラピュティクス アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0513060A external-priority patent/GB0513060D0/en
Priority claimed from GB0515997A external-priority patent/GB0515997D0/en
Application filed by ナブリヴァ セラピュティクス アクチエンゲゼルシャフト filed Critical ナブリヴァ セラピュティクス アクチエンゲゼルシャフト
Publication of JP2008546810A publication Critical patent/JP2008546810A/ja
Publication of JP2008546810A5 publication Critical patent/JP2008546810A5/ja
Application granted granted Critical
Publication of JP5373393B2 publication Critical patent/JP5373393B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/93—Spiro compounds
    • C07C2603/95—Spiro compounds containing "not free" spiro atoms
    • C07C2603/98—Spiro compounds containing "not free" spiro atoms containing at least one ring with more than six ring members
    • C07C2603/99—Spiro compounds containing "not free" spiro atoms containing at least one ring with more than six ring members containing eight-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2008518554A 2005-06-27 2006-06-26 ヒドロキシアミノ基またはアシルオキシアミノシクロアルキル基を含むプレウロムチリン誘導体 Expired - Fee Related JP5373393B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0513060.4 2005-06-27
GB0513060A GB0513060D0 (en) 2005-06-27 2005-06-27 Organic compounds
GB0515997.5 2005-08-03
GB0515997A GB0515997D0 (en) 2005-08-03 2005-08-03 Organic compounds
PCT/AT2006/000260 WO2007000004A1 (en) 2005-06-27 2006-06-26 Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group

Publications (3)

Publication Number Publication Date
JP2008546810A JP2008546810A (ja) 2008-12-25
JP2008546810A5 JP2008546810A5 (cg-RX-API-DMAC7.html) 2012-10-25
JP5373393B2 true JP5373393B2 (ja) 2013-12-18

Family

ID=36764461

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008518554A Expired - Fee Related JP5373393B2 (ja) 2005-06-27 2006-06-26 ヒドロキシアミノ基またはアシルオキシアミノシクロアルキル基を含むプレウロムチリン誘導体

Country Status (5)

Country Link
US (1) US7790767B2 (cg-RX-API-DMAC7.html)
EP (2) EP1896404B1 (cg-RX-API-DMAC7.html)
JP (1) JP5373393B2 (cg-RX-API-DMAC7.html)
TW (1) TW200730488A (cg-RX-API-DMAC7.html)
WO (1) WO2007000004A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1896404B1 (en) * 2005-06-27 2014-09-17 Nabriva Therapeutics AG Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group
EP1808431A1 (en) 2006-01-16 2007-07-18 Nabriva Therapeutics Forschungs GmbH Mutilin derivatives and their use as pharmaceutical
EP1972618A1 (en) * 2007-03-20 2008-09-24 Nabriva Therapeutics AG Pleuromutilin derivatives for the treatment of diseases mediated by microbes
JP5322927B2 (ja) 2007-05-24 2013-10-23 杏林製薬株式会社 14位置換基に複素芳香環カルボン酸構造を有するムチリン誘導体
EP2159220A1 (en) * 2008-09-02 2010-03-03 Nabriva Therapeutics AG Organic compounds
AR090010A1 (es) 2011-04-15 2014-10-15 Bayer Cropscience Ag 5-(ciclohex-2-en-1-il)-penta-2,4-dienos y 5-(ciclohex-2-en-1-il)-pent-2-en-4-inos sustituidos como principios activos contra el estres abiotico de las plantas, usos y metodos de tratamiento
CN102229580B (zh) * 2011-05-12 2014-02-26 南通大学 新型截短侧耳素衍生物、其制备方法及其医药用途
BR112014000267A2 (pt) 2011-07-04 2016-09-20 Bayer Ip Gmbh utilização de isoquinolinonas, isoquinolinedionas, isoquinolinetrionas e dihidroisoquinolinonas substituídas ou, em cada caso, sais das mesmas como agentes ativos contra o stress abiótico em plantas
CN103204787B (zh) * 2012-01-17 2014-10-01 北京艾百诺科技有限公司 含有取代方酸的乙酸妙林酯及其应用
EP3096751B1 (en) * 2014-01-22 2021-01-06 Nabriva Therapeutics GmbH 12-epi-pleuromutilins
PT3310331T (pt) * 2015-06-17 2021-01-19 Nabriva Therapeutics GmbH Formulações farmacêuticas injetáveis de lefamulina
TWI762573B (zh) 2017-02-10 2022-05-01 奧地利商納畢瓦治療有限責任公司 截短側耳素之純化
US20230174472A1 (en) * 2020-04-17 2023-06-08 Nabriva Therapeutics GmbH Therapeutic use of pleuromutilins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3054875B2 (ja) * 1995-02-13 2000-06-19 株式会社小松製作所 プラズマトーチ
UY25225A1 (es) * 1997-10-29 2000-12-29 Smithkline Beecham Plc Derivados de pleuromutilina utiles como agentes antimicrobianos
CO5150194A1 (es) * 1999-01-27 2002-04-29 Abbott Lab Inhibidores hidroxamato inversos de las metalopreteinasas matriciales
GB0017031D0 (en) * 2000-07-11 2000-08-30 Biochemie Gmbh Antimicrobials
WO2003040103A1 (en) * 2001-11-02 2003-05-15 Bristol-Myers Squibb Company β-SULFONE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE)
GB0207495D0 (en) * 2002-03-28 2002-05-08 Biochemie Gmbh Organic compounds
GB0209262D0 (en) * 2002-04-23 2002-06-05 Biochemie Gmbh Organic compounds
EP1896404B1 (en) * 2005-06-27 2014-09-17 Nabriva Therapeutics AG Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group

Also Published As

Publication number Publication date
TW200730488A (en) 2007-08-16
WO2007000004A1 (en) 2007-01-04
EP1896404A1 (en) 2008-03-12
EP2298733A2 (en) 2011-03-23
US20090306203A1 (en) 2009-12-10
EP1896404B1 (en) 2014-09-17
EP2298733B1 (en) 2016-05-25
US7790767B2 (en) 2010-09-07
EP2298733A3 (en) 2011-12-14
JP2008546810A (ja) 2008-12-25

Similar Documents

Publication Publication Date Title
KR101478593B1 (ko) 미생물에 의해 매개되는 질병 치료용 플루로뮤틸린 유도체
JP5173763B2 (ja) 抗細菌活性を有するプレウロムチリン誘導体
JP5613562B2 (ja) 有機化合物
JP5628173B2 (ja) 有機化合物
JP5489467B2 (ja) ムチリン派生物および調合薬としてのそれらの使用
JP2008546810A (ja) ヒドロキシアミノ基またはアシルオキシアミノシクロアルキル基を含むプレウロムチリン誘導体
AU2001276389A1 (en) Pleuromutilin derivatives having antibacterial activity
TWI414511B (zh) 有機化合物
HK1125624B (en) Mutilin derivatives adn their use as pharmaceutical
HK1109889A (en) Mutilin derivatives and their use as pharmaceutical
MXPA05001761A (es) Derivado de acido r(+)-2-amino-3-hidroxipropanoico con accion glicinergica.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120306

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120403

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120410

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20120906

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130725

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130801

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130827

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130919

R150 Certificate of patent or registration of utility model

Ref document number: 5373393

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

S303 Written request for registration of pledge or change of pledge

Free format text: JAPANESE INTERMEDIATE CODE: R316303

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S803 Written request for registration of cancellation of provisional registration

Free format text: JAPANESE INTERMEDIATE CODE: R316805

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees